Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis
JAMA Dermatology · 01.05.2024 · 160 (5) · 550
DOI: 10.1001/jamadermatol.2023.5439 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JAMA Dermatology, erschienen am 01.05.2024. Verfasst von Lourdes M Pérez-Chada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Psoriasis, Quality of Life. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Importance Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQL) exist for patients with psoriasis. Evidence for the content validity and other measurement properties of these PROMs is critical to determine which HRQL PROMs could be recommended for use.
Objective
To systematically review the validity of HRQL-focused PROMs used in patients with psoriasis. Evidence Review Using PubMed and Embase, full-text articles published in English or Spanish on development or validation studies for psoriasis-specific, dermatology-specific, or generic HRQL PROMs were included. Development studies included original development studies, even if not studied in psoriasis patients per Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations. If a study included multiple diagnoses, more than 50% of patients had to have psoriasis or psoriasis-specific subgroup analyses available. Data extraction and analysis followed the COSMIN guidelines. Two independent reviewers extracted and analyzed the data, including PROM characteristics, quality of measurement properties (structural validity, internal consistency, cross-cultural validity, reliability, measurement error, criterion validity, construct validity, and responsiveness), and level of evidence. PROMs were classified into 3 levels of recommendations: (1) PROM recommended for use; (2) PROM requires further validation; and (3) PROM not recommended for use.
Findings
Overall, 97 articles were identified for extraction. This included 19 psoriasis-specific, 8 skin-specific, and 6 generic PROMs. According to COSMIN standards, most measures identified received a B recommendation for use, indicating their potential but requiring further validation. Only the Rasch reduced version of the Impact of Psoriasis Questionnaire (IPSO-11 Rasch) received an A recommendation for use given that it had sufficient content validity, structural validity, and internal consistency. Conclusions and Relevance This study identified a significant lack of information concerning the quality of HRQL measures in psoriasis. This gap in knowledge can be attributed to the fact that traditional measures were developed using validation criteria that differ from the current standards in use. Consequently, additional validation studies in accordance with contemporary standards will be useful in aiding researchers and clinicians in determining the most suitable measure for assessing HRQL in patients with psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
- Department of Dermatology, University of Utah, Salt Lake City.
- Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Dermatology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Department of Dermatology, University of California, Los Angeles, Los Angeles.
Förderung
- NIAMS NIH HHS
Zitieren
APA
Pérez-Chada, L. M., Hopkins, Z. H., Balak, D. M. W., Rashid, S., Creadore, A., Chu, B., Villa, C., Woodbury, M. J., Armstrong, A. W., Strand, V., Gottlieb, A. B., Merola, J. F., & Barbieri, J. S. (2024). Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis. JAMA Dermatology, 160(5), 550. https://doi.org/10.1001/jamadermatol.2023.5439
Vancouver
Pérez-Chada LM, Hopkins ZH, Balak DMW, Rashid S, Creadore A, Chu B, et al. Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis. JAMA Dermatology. 2024;160(5):550. doi:10.1001/jamadermatol.2023.5439
BibTeX
@article{PrezChada2024,
author = {Pérez-Chada, Lourdes M and Hopkins, Zachary H and Balak, Deepak M W and Rashid, Sarem and Creadore, Andrew and Chu, Brian and Villa, Camila and Woodbury, Michael J and Armstrong, April W and Strand, Vibeke and Gottlieb, Alice B and Merola, Joseph F and Barbieri, John S},
title = {Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {5},
pages = {550},
doi = {10.1001/jamadermatol.2023.5439}
}
EUVIMED